Marinomed Biotech AG (MARI.VI)
Vienna · EUR · Healthcare · Biotechnology
€4.00 (+0.00%) as of
Key statistics
- Market cap
- 8.00M
- P/E (TTM)
- 0.40
- Forward P/E
- 1.75
- EPS (TTM)
- 10.1000
- Dividend yield
- 0.00%
- 52-week range
- 2.2000 – 21.0000
- Beta
- -0.20
- Revenue (TTM)
- 7.96M
- Profit margin
- 226.36%
- Volume
- 85.00
About Marinomed Biotech AG
Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development; and Tacrosolv for the treatment of inflammatory eye diseases in Phase II clinical studies. The company also develops Satiasolv for pain immune reactions in the preclinical development phase. In addition, it provides Solv4U for formulation development and biopharmaceutical testing services. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Korneuburg, Austria
- Employees
- 32
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.